HCP
NVCR icon

Hexagon Capital Partners’s NovoCure NVCR Stock Holding History

Hexagon Capital Partners’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-124
Closed -$2.21K – 1162
2025
Q1 		$2.21K Buy
124
+112
+933% +$2.54K ﹤0.01% 1377
2024
Q4 		$358 Buy
12
+8
+200% +$169 ﹤0.01% 1724
2024
Q3 		$63 Buy
+4
New +$73 ﹤0.01% 1555

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Hexagon Capital Partners's NVCR Position: Q2 2025 in Review

Hexagon Capital Partners sold out of NovoCure (NVCR) in Q2 2025, closing a stake of 124 shares — an estimated $2.21K sold.

Hexagon Capital Partners first reported a position in NVCR in Q3 2024 and held it in 3 quarters. The position peaked at $2.21K in Q1 2025. 242 funds tracked by Wall St. Rank hold NVCR as of Q2 2025.

  • Hexagon Capital Partners reported no remaining NovoCure position as of Q2 2025 after selling out during the quarter.
  • Hexagon Capital Partners sold 124 NovoCure shares in Q2 2025, an estimated $2.21K.
  • Hexagon Capital Partners first reported a position in NovoCure in Q3 2024 and held it in 3 quarters.
  • Hexagon Capital Partners's NovoCure position peaked at $2.21K in Q1 2025.
  • 242 funds tracked by Wall St. Rank held NovoCure as of Q2 2025.

Based on Hexagon Capital Partners's 13F filing for Q2 2025, filed 11 Aug 2025.